MARIANNA PAPADOPOULOU

Dr. MARIANNA PAPADOPOULOU

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in In Vivo
Verified
Journal Article
Open access
PDF file
MARIANNA PAPADOPOULOUMARIANNA PAPADOPOULOU
MARIANNA PAPADOPOULOU
MSMagda Stamou
Magda Stamou
DBDaphne Bakalidou
Daphne Bakalidou
CMChristos Moschovos
Christos Moschovos
VZVasiliki Zouvelou
Vasiliki Zouvelou
GTGeorgios Tsivgoulis
Georgios Tsivgoulis
Background/Aim: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment, resulting in pain, numbness, instability, and thus affecting quality of life (QoL), occasionally leading to discontinuation of chemotherapy. Pharmacological treatments are not sufficient. Non-pharmacological interventions (NPIs) have also been tried. This study aimed to systematically review the efficacy of NPIs on pain and QoL in patients suffering from CIPN. Materials and Methods: The databases searched were Pubmed, Cohrane, and Scopus for randomized controlled trials (RCTs) published in the last 5 years (2017-2022). Studies were considered eligible, if they assessed adult patients suffering from CIPN because of any chemotherapeutic drug for any type and any stage of cancer and if study protocols included non-pharmacological intervention with a structured protocol. Results: A total of 1,496 records were identified. Finally, 10 RCTs including 495 patients (253 in the intervention group and 242 in the control group) were included for meta-analysis. Intervention protocols included acupuncture (n=6), exercise (n=3), and yoga (n=1). NPIs significantly reduced neuropathic pain. However, the effect on QoL was not significant. Conclusion: NPIs are beneficial in the treatment of pain in patients with CIPN but their impact on QoL is not statistically supported. Larger sample sizes, more homogenous in outcome measures and interventions are needed to further explore NPIs’ efficacy on CIPN symptoms.

22 July 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
VPVasileios C Papatsimpas
Vasileios C Papatsimpas
SVSotiria Dimitrios Vrouva
Sotiria Dimitrios Vrouva
George PapathanasiouGeorge Papathanasiou
George Papathanasiou
MARIANNA PAPADOPOULOUMARIANNA PAPADOPOULOU
MARIANNA PAPADOPOULOU
CBChristina Bouzineki
Christina Bouzineki
Daphne BakalidouDaphne Bakalidou
Daphne Bakalidou
This randomized controlled trial aims to investigate the effect of 12 weeks of therapeutic exercise on cognitive function and daily activities in patients with mild Alzheimer’s disease (AD). A total of 171 patients with mild AD from the Amarousion Day Care Center of the Alzheimer Society of Athens and the Athens General Hospital “G. Gennimatas” were randomly divided into three groups. Group A (aerobic and resistance exercise, n = 57), group B (resistance exercise, n = 57), and group C (control group, n = 57). Group A followed a weekly program consisting of 5 days with 30 min walking and 3 days with resistance exercises for about 45 min. Group B followed only a resistance exercise program, the same as group A. Group C did not participate in any exercise program. After the intervention, cognitive function was assessed with the Cognitive Examination-Revised (ACE-R), Trail Making Test A-B (TMT A-B), and Digit Span Test Forward and Backward (DST F-B) and daily activities with the instrumental activities of daily living scale (IADLs). A significant intervention effect was observed for all outcome measures (global cognitive function and instrumental activities of daily living). ANCOVA Bonferroni corrected post hoc tests revealed that the aerobic and resistance group improved compared to the control group on all measurement scales. The resistance group also showed an improvement compared to the control group. No significant effects were found between the aerobic and resistance group and the resistance group in any of the outcome measures.

24 September 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
MARIANNA PAPADOPOULOUMARIANNA PAPADOPOULOU
MARIANNA PAPADOPOULOU
APApostolos Papapostolou
Apostolos Papapostolou
EBEleni Bakola
Eleni Bakola
VMVasilios G. Masdrakis
Vasilios G. Masdrakis
CMChristos Moschovos
Christos Moschovos
IMIoannis Michopoulos
Ioannis Michopoulos

2 September 2025 in Biomechanics
Verified
Journal Article
Open access
PDF file
ATANNA TSIAKIRI
ANNA TSIAKIRI
Spyridon PlakiasSpyridon Plakias
Spyridon Plakias
GGGeorgios Giarmatzis
Georgios Giarmatzis
GTGEORGIA TSAKNI
GEORGIA TSAKNI
FCFoteini Christidi
Foteini Christidi
Pinelopi VlotinouPinelopi Vlotinou
Pinelopi Vlotinou
Background/Objectives: Multiple sclerosis (MS) often leads to gait impairments, even in early stages, and can affect autonomy and quality of life. Traditional assessment methods, while widely used, have been criticized because they lack sensitivity to subtle gait changes. This scoping review aims to map the landscape of advanced gait analysis technologies—both wearable and non-wearable—and evaluate their application in detecting, characterizing, and monitoring possible gait dysfunction in individuals with MS. Methods: A systematic search was conducted across PubMed and Scopus databases for peer-reviewed studies published in the last decade. Inclusion criteria focused on original human research using technological tools for gait assessment in individuals with MS. Data from 113 eligible studies were extracted and categorized based on gait parameters, technologies used, study design, and clinical relevance. Results: Findings highlight a growing integration of advanced technologies such as inertial measurement units, 3D motion capture, pressure insoles, and smartphone-based tools. Studies primarily focused on spatiotemporal parameters, joint kinematics, gait variability, and coordination, with many reporting strong correlations to MS subtype, disability level, fatigue, fall risk, and cognitive load. Real-world and dual-task assessments emerged as key methodologies for detecting subtle motor and cognitive-motor impairments. Digital gait biomarkers, such as stride regularity, asymmetry, and dynamic stability demonstrated high potential for early detection and monitoring. Conclusions: Advanced gait analysis technologies can provide a multidimensional, sensitive, and ecologically valid approach to evaluating and detecting motor function in MS. Their clinical integration supports personalized rehabilitation, early diagnosis, and long-term disease monitoring. Future research should focus on standardizing metrics, validating digital biomarkers, and leveraging AI-driven analytics for real-time, patient-centered care.

14 May 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MARIANNA PAPADOPOULOUMARIANNA PAPADOPOULOU
MARIANNA PAPADOPOULOU
MSMaria Ioanna Stefanou
Maria Ioanna Stefanou
EBEleni Bakola
Eleni Bakola
CMCHRISTOS MOSCHOVOS
CHRISTOS MOSCHOVOS
AAAthanasia Athanasaki
Athanasia Athanasaki
Georgios TsivgoulisGeorgios Tsivgoulis
Georgios Tsivgoulis
Background: Alzheimer’s disease (AD) is the most common cause of dementia. In addition to cognitive decline, non-cognitive symptoms, including dysautonomia, have been reported, although these symptoms are rarely acknowledged by patients. Dysautonomia in AD is thought to arise from either cholinergic deficits or hypothalamic involvement. A wide range of tests has been used to investigate the role of the autonomic nervous system; however, the results have been inconsistent. Aim: To systematically review all published research investigating autonomic nervous system (ANS) involvement in patients with AD. A comprehensive literature search was conducted in December 2024 across the following databases: PubMed, Cochrane Library, ScienceDirect, and Scopus. Results: A total of 1422 records were identified, of which 30 studies fulfilled the inclusion criteria and were included in the review. Several autonomic tests were employed, with Heart Rate Variability (HRV) being the most frequently used. Other tests included assessments of orthostatic hypotension (OH), postprandial hypotension (PPH), sympathetic skin response (SSR), the tilt test, 123I-MIBG cardiac scintigraphy, norepinephrine (NE) measurements in serum and cerebrospinal fluid, and baroreflex sensitivity. In most studies, AD patients were compared to either healthy controls or patients with other types of dementia. Discussion: The primary finding of this review is that, although patients with AD rarely report dysautonomic symptoms, they frequently exhibit abnormal results on various autonomic tests. In some cases, these findings were sufficient to differentiate AD patients from healthy controls as well as from patients with Diffuse Lewy Body disease (DLB). The inconsistency in reporting symptoms, along with the variability in test results, suggests that autonomic dysfunction in AD may be under-recognized and warrants further investigation. Conclusions: The heterogeneity of the included studies limits the generalizability of the results. However, given the potential impact of dysautonomia on both quality of life and mortality, it is recommended that AD patients be systematically assessed for autonomic dysfunction. Even in the absence of overt symptoms, appropriate treatment should be considered where indicated to mitigate potential risks.

6 January 2020 in Journal of Developmental and Physical Disabilities
Verified
Journal Article
Closed access
PDF file
MARIANNA PAPADOPOULOUMARIANNA PAPADOPOULOU
MARIANNA PAPADOPOULOU
SSSophia Stasi
Sophia Stasi
DBDaphne Bakalidou
Daphne Bakalidou
EPEffie Papageorgiou
Effie Papageorgiou
ATAristi Tsokani
Aristi Tsokani
GPGeorge Papathanasiou
George Papathanasiou